Last reviewed 2026-04-19 · How we verify

PA32540 and celecoxib

POZEN · Phase 1 active Small molecule

PA32540 and celecoxib is a Small molecule drug developed by POZEN. It is currently in Phase 1 development.

At a glance

Generic name	PA32540 and celecoxib
Sponsor	POZEN
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With Celecoxib (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PA32540 and celecoxib CI brief — competitive landscape report
PA32540 and celecoxib updates RSS · CI watch RSS
POZEN portfolio CI

Frequently asked questions about PA32540 and celecoxib

What is PA32540 and celecoxib?

PA32540 and celecoxib is a Small molecule drug developed by POZEN.

Who makes PA32540 and celecoxib?

PA32540 and celecoxib is developed by POZEN (see full POZEN pipeline at /company/pozen).

What development phase is PA32540 and celecoxib in?

PA32540 and celecoxib is in Phase 1.

Manufacturer: POZEN — full pipeline
Compare: PA32540 and celecoxib vs similar drugs
Pricing: PA32540 and celecoxib cost, discount & access